Nama's AI scorecard currently rates Henry Schein Buy (5.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is HSIC's P/E ratio?

Henry Schein trades at a trailing price-to-earnings ratio of 16.2.

When does HSIC report earnings?

Henry Schein's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $1.40.

What is the HSIC price target?

The median analyst price target from 15 analysts is $100.00, with a range of $64.00 – $110.00.

Is HSIC Shariah compliant?

Nama's AAOIFI-style screen reads Henry Schein as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Henry Schein (HSIC)

Healthcare · Medical Distribution · NASDAQ

S&P 500

Henry Schein (HSIC) is a Healthcare company in the Medical Distribution industry. It has a market capitalization of $9.51B, a trailing price-to-earnings ratio of 16.2 and a free-cash-flow yield of 5.0%. Over the most recent reported fiscal year, revenue grew 4.0% and free cash flow per share fell 17.2%. Nama's AI scorecard rates it Buy, 5.9 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 5.9/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Rising · +19.4% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-7.2%

How far the last close sits under the highest price of the past five years.

Market cap	$9.51B
Trailing P/E	16.2
Price / book	3.0
Price / sales	0.7
FCF yield	5.0%
Dividend yield	—
Gross margin	31.3%
Operating margin	5.7%
Net margin	3.0%
Revenue growth (YoY)	+4.0%
Revenue growth (3-yr annual)	+1.4%
EPS growth (YoY)	+4.8%
FCF/share growth (YoY)	-17.2%
Beta	0.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Distribution

HSIC earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate $1.40). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	$1.37	$1.36	+0.7%	$3.47B
Q2 2026	Aug 4, 2026	$1.27	$1.24	+2.4%	$3.46B
Q1 2026	May 5, 2026	$1.32	$1.22	+8.2%	$3.37B
Q4 2025	Feb 24, 2026	$1.34	$1.29	+3.9%	$3.44B

HSIC analyst price target

Median target $100.00 from 15 analysts, ranging $64.00 – $110.00.

Medical Distribution peers

Ticker	Company	Market cap	P/E
MCK	McKesson	$122.48B	24.9
COR	Cencora	$63.65B	18.6
CAH	Cardinal Health	$62.92B	23.3
AHG	Akso Health Group	$1.16B	—

Explore live HSIC data on Nama Insights →

Recent Congressional trades

Henry Schein trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Julie Johnson	House	Sell	$1,001 - $15,000	May 14, 2025
Rob Bresnahan	House	Buy	$1,001 - $15,000	May 8, 2025
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Apr 7, 2025
Susan M Collins	Senate	Buy	$1,001 - $15,000	—
Susan M Collins	Senate	Buy	$1,001 - $15,000	—

HSIC FAQ

Is HSIC a buy?: Nama's AI scorecard currently rates Henry Schein Buy (5.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is HSIC's P/E ratio?: Henry Schein trades at a trailing price-to-earnings ratio of 16.2.
When does HSIC report earnings?: Henry Schein's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $1.40.
What is the HSIC price target?: The median analyst price target from 15 analysts is $100.00, with a range of $64.00 – $110.00.
Is HSIC Shariah compliant?: Nama's AAOIFI-style screen reads Henry Schein as Not Shariah Compliant. At least one of the three ratios or the industry test failed.